pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe.

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

pharmaphorum

JUNE 23, 2022

billion in potential milestones if the project advances through development and onto the market. Systemic administration of gene-editing drugs would avoid that process with an “off-the-shelf” option for a one-shot, potentially curative treatment for diseases associated with genetic mutations.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

APRIL 23, 2021

billion in milestone payments in the deal, which will focus on using small-molecule compounds to “fine tune” the effects of genetic medicines in the body. The approach relies on the use of drug responsive domains (DRDs) on the gene-editing medicine, which can be used to either increase or decrease protein expression.

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

FEBRUARY 23, 2022

Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies. Next Generation Sequencing (NGS) Library Preparation Kits. NGS Library Preparation Kits Market. Players Engaged in the Domain.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

DECEMBER 28, 2020

About Fulgent Genetics. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. TEMPLE CITY, Calif.,

Genetics 52

Genetics Sales Gene Sequencing Marketing 52

pharmaphorum

AUGUST 21, 2020

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing. Longwall Ventures and Agilent have both returned to invest in the Series A, which on this occasion was led by BlueYard Capital.

DNA 59

DNA Gene Sequencing Genetics FDA Approval 59